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CASE REPORT
Rapid healing of a patient with dramatic 
subacute combined degeneration of spinal 
cord: a case report
Florian C. Roessler1,2* and Stephanie Wolff1
Abstract 
Background: Prevalence of cobalamin deficiency is high especially in older patients and an immediate therapy start 
is necessary to prevent irreversible neurological damages. Unfortunately, the diagnosis of cobalamin deficiency is dif-
ficult and at present, there is no consensus for diagnosis of this deficiency. Therefore, we aim to elucidate a meaning-
ful diagnostic pathway by a case report with an initially misleading medical history.
Case presentation: A 57 year-old Caucasian man suffering from dramatic myelosis of the cervical posterior columns. 
Apart from associated neurological symptoms (tactile hypaesthesia, reduced vibration sensation, loss of stereognosis 
and of two-point-discrimination) there were no further complaints; especially no gastrointestinal, haematological 
or psychiatric disorders were provable. Cobalamin (vitamin B12) serum level was normal. The diagnosis of subacute 
combined degeneration of spinal cord was confirmed by an elevated methylmalonic acid, and hyperhomocysteine-
mia. Cobalamin deficiency was caused by asymptomatic chronic atrophic inflammation of the stomach with a lack 
of intrinsic factor producing gland cells. This was revealed by increased gastrin and parietal cell antibodies and finally 
confirmed by gastroscopy. Parenteral substitution of cobalamin rapidly initiated regeneration.
Conclusions: This case demonstrates that normal cobalamin serum levels do not rule out a cobalamin deficiency. 
In contrast, path-breaking results can be achieved by determining homocysteine, holotranscobalamin, and methyl-
malonic acid.
Keywords: Subacute combined degeneration of spinal cord, Cobalamin, Methylmalonic acid, Holotranscobalamin, 
Homocysteine, Autoimmune gastritis
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Background
Prevalence of cobalamin deficiency in general population 
is about 4% [1]. In older patients (>65  years) functional 
cobalamin deficiency was found in 10–30% of all cases [2, 
3]. Frequently, the diagnosis of cobalamin deficiency is 
difficult, because anaemia or macrocytosis are frequently 
absent, cobalamin concentrations are mostly borderline 
[4], and solely psychiatric syndromes are present which 
are sometimes variable, unspecific, subtle, and uneven 
in rate [5, 6]. Therefore, the exact prevalence of clinically 
significant cobalamin deficiency is not known [7]. Early 
diagnostic and an immediate therapy start are necessary 
to prevent irreversible neurological damages [8]. How-
ever, at present, there is no consensus or guideline for the 
diagnosis of this deficiency.
Humans are not able to synthesize cobalamin. Food 
of animal source is the only natural source of cobala-
min in human diet. In the stomach, ingested cobala-
min is detached from its protein-binding by pepsin and 
hydrochloric acid. Then, it is bound to the glycopro-
teins haptocorrin and intrinsic factor (IF) secreted by 
gastric mucosa. The majority of the required cobalamin 
uptake takes place in the terminal ileum by binding of 
the cobalamin-IF-complex to receptors of the mucosa 
cells [9]. Inside the enterocytes cobalamin is released and 
bound to its carrier protein transcobalamin II. Thereby, 
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holotranscobalamin (holoTC) originates. In this way 
cobalamin circulates in the blood and gets absorbed by 
body cells. In the cytoplasm, the released cobalamin is 
converted into methylcobalamin. In the mitochondria, 
cobalamin is converted into adenosylcobalamin.
Methylcobalamin and folates are co-factors in the 
methionine-synthase mediated conversion of homo-
cysteine to methionine, which is essential for nucleotide 
synthesis and genomic and non-genomic methylation 
[5]. Therefore, a lack of methylcobalamin leads to a dis-
turbed cell multiplication. Homocysteine accumulates at 
the same time. High concentrations of homocysteine are 
associated with an increased cardiovascular risk [10–13]. 
Furthermore, homocysteine seems to have neurotoxic 
properties causing vascular dementia and Alzheimer’s 
disease [14, 15]. Adenosylcobalamin is a co-factor for 
methylmalonyl-CoA mutase converting methylmalonyl-
CoA to succinyl-CoA. Succinyl-CoA plays a decisive 
role in the citric acid cycle. Therefore, a lack of adeno-
sylcobalamin disrupts the proliferation, maturation, and 
regeneration of neurons and leads to an accumulation of 
methylmalonic acid (MMA).
Clinically, cobalamin deficiency is manifested mainly 
by haematological and neuropsychiatric symptoms. Fre-
quently, these symptoms arise before the lower limit 
value of cobalamin is reached [16]. In contrast, mac-
rocytosis evolves later. Subacute combined degenera-
tion of spinal cord (SACD) is a frequent consequence 
of cobalamin deficiency. In most cases this disease is 
restricted to the posterior columns of the upper cervical 
and thoracic segments associated with tactile sensibility 
loss and proprioceptive problems [4, 17, 18]. White mat-
ter damages comply with an abnormal myelination [19] 
probably caused by (1) reduced methyl group availabil-
ity resulting from a lack of methylcobalamin [17, 20] and 
(2) nonphysiological fatty acids toxicity resulting from a 
decreased activity of the adenosylcobalamin dependent 
methylmalonyl-CoA mutase [20]. Focal gliosis results 
from homocysteine-induced toxicity to the endothe-
lium [20]. Subsequently, a less extended demyelination 
of the spinocerebellar tracts and also an involvement of 
the lateral columns and pyramidal tracts can be seen, 
which typically gets started in the thoracic cord, but can 
extend to involve other levels [17]. This might lead to 
ataxia, paresis, hyperreflexia, and bladder dysfunction. 
Later, peripheral nerves, cerebrum, and in rare cases also 
optic nerves are damaged [17]. Additionally, patients may 
become depressed or suffer from psychosis [4, 18]. Many 
patients have a macrocytosis [21], glossitis and cutane-
ous manifestations like hyperpigmentation, hair and nail 
changes [22].
Common reasons for cobalamin deficiencies can be 
divided into four groups (Table  1): diminished supply 
of cobalamin, disruption of cobalamin processing in the 
stomach (caused for instance by an autoimmune gastri-
tis resulting from antibodies reacting with parietal cells 
leading to a decreased emission of intrinsic factor), intes-
tinal resorption problems, and defective transport and 
intracellular metabolism [21, 23, 24].
Finally, cobalamin deficiency with inconspicuous blood 
values for cobalamin and holoTC is common in patients 
suffering from kidney diseases [25]. Probably, this is 
caused by a disrupted cellular absorption of holoTC and 
by secondary accumulation of holoTC resulting from 
a disturbed filtration of transcobalamin in the kidneys 
[26]. This leads to an intracellular lack of cobalamin and 
to increased values of cobalamin dependent metabolites 
(MMA and homocysteine). On the other hand, patients 
suffering from kidney diseases might also have increased 
values of MMA although no cobalamin deficiency is pre-
sent [2, 25]. Therefore, Herrmann et  al. recommend in 
cases of renal dysfunction to verify a real cobalamin defi-
ciency by detection of a significant reduction of MMA 
(ΔMMA > 200 nmol/l) after probatory substitution with 
cobalamin [7] (Fig. 1).
Clinical improvement and full recovery from myelopa-
thy can occur when substitution of cobalamin and folic 
acid is started in the early stages of the disease [27].
We would like to present a case, in which medical 
history and imaging initially pointed to a traumatic or 
malignant cause of solely neurological complaints. This 
Table 1 Common reasons for cobalamin deficiencies
Diminished supply
 Vegan nutrition
 Alcohol abuse
 Parasitic infections (e.g. fish tapeworm)
 Reduced food intake (older people)
 Pregnancy (relative deficit)
Disruption of cobalamin processing in the stomach
 Gastric bypass/post-gastrectomy
 Chronic gastritis (e.g. induced by alcohol abuse, helicobacter pylori infection)
 Autoimmune gastritis resulting from antibodies reacting with parietal cells 
(pernicious anaemia)
 Proton pump inhibitors and H2-receptor antagonists (sustained release of 
cobalamin)
 Metformin, cytostatics, methyldopa, aminoglycosides e.g. (medicinal side effect)
Intestinal resorption problems
 Intestinal bypass/ileal resection
 Pathogenic intestinal flora
 Ulcerating colitis
 Crohn’s disease
 Zollinger-Ellison syndrome
 Imerslund-Gräsbeck syndrome
Defective transport and intracellular metabolism
 Congenital deficiency in transcobalamin II
 Congenital deficiency in various intracellular enzymes
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case illustrates the need of a targeted laboratory diagnos-
tic when clinical examination raises reasonable suspicion 
of SACD.
Case presentation
Medical history
Seven months before presentation, a 57 year-old Cauca-
sian man fell off a two meter high roof, suffering from a 
left-hand serial rip fracture and a fracture of the proces-
sus transversi of the thoracic vertebral bodies 6 and 7. 
Three months later, he recognized for the first time a sus-
tainable tactile hypaesthesia and paraesthesia beginning 
in both hands and extending to both shoulders and to 
the thorax double-sided within the following months. He 
also described a narrowed sensation within the thorax. 
Three and a half months after the start of sensibility loss 
a magnetic resonance tomography of the cervical spine 
was performed outward. There were no other diseases or 
allergies and no sustained medication intake. Nutritional 
status was normal with no restrictive dietary habits.
Physical examination
The patient suffered from a symmetric hypaesthesia 
of both arms reaching from the fingers up to the mid-
dle of the upper arms and double-sided at the thorax 
from Th2 to Th10. He had a pathological two-point-
discrimination at both arms and at the thorax (he only 
recognized distances >7 cm) and a disturbed stereogno-
sis: the patient was not able to distinguish a pen from 
a rolled-up bandage. Additionally, he offered a reduced 
Fig. 1 Diagnostic pathway to prove cobalamin deficiency. Up to now, no consensus exists about the best diagnostic pathway to prove cobalamin 
deficiency [7]. This pathway is a modification of recommendations made by Herrmann et al. [7]. MMA methylmalonic acid, holoTC holotranscobala-
min. Limit values for MMA and holoTC specified here are in accordance with those of other authors [7, 24, 29, 32]. For follow-up we recommend the 
measurement of homocysteine (normal: 5.0–15.0 µmol/l; pathological threshold: >25 µmol/l) [28]
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pallaesthesia: vibration sensibility was reduced to 3–4/8 
on both sides of the distal radius, and to 0/8 on both 
malleoli mediales and to 6/8 on both tibiae. Perception 
of temperature and pain and sense of position were not 
affected. Further examination did not reveal any abnor-
malities. Gait was unremarkable, reflexes were normal: 
There were no pyramidal tract symptoms, no pareses 
and no mental abnormalities. The patient was of good 
general condition with a normal weight. He had no 
glossitis.
Diagnostic
The outward performed 3 Tesla MRI revealed a hyperin-
tense T2w signal alteration in the dorsal cervical spine, 
corresponding to an intramedullar lesion reaching from 
the first to the fifth cervical vertebral body (Fig. 2a).
Motor evoked potentials (MEP) detected a marginal 
central-motoric latency to the left arm, indicating a 
potential pyramidal tract lesion. Somatosensory evoked 
potentials (SSEP) uncovered a medianus SSEP with mar-
ginal values on the left side, normal results on the right 
side and pathological values of the tibialis SSEP on both 
sides. Visual evoked potentials (VEP) showed prolonged 
latencies. In gastroscopy, the mucosa was atrophic. His-
tology of gastric biopsy revealed a chronic-atrophic 
inflammation of corpus ventriculi with a lack of intrin-
sic factor-producing gland cells and with a micronodular 
hyperplasia of neuroendocrine cells, indicating an auto-
immune gastritis.
The laboratory diagnostic (Table  2) revealed elevated 
parietal cell antibodies (titer 1:640, normal:  ≤1:20). 
Serum cobalamin concentration was in the lower nor-
mal range (197  pg/ml, normal: 150–900  pg/ml) and 
folic acid was normal (18.7 ng/ml, normal: 3–20 ng/ml), 
whereas MMA was highly elevated (40,800 nmol/l, nor-
mal: 50–300 nmol/l). In addition, we found an increased 
homocysteine of 50.8  µmol/l (normal: 5.0–15.0  µmol/l) 
and a high gastrin level (615 pg/ml, normal: 13–115 pg/
ml). Blood cell count was normal. Further labora-
tory diagnostics did not reveal any renal dysfunction. 
Analysis of the cerebrospinal fluid revealed inconspicu-
ous findings: a slight elevation of protein (530  mg/l, 
normal:  <450  mg/l) and of lactate (2.4  mmol/l, nor-
mal: <1.9 mmol/l), an unremarkable cell count (1 cell/µl), 
and no oligoclonal bands.
Therapy
Our patient was treated with i.m. injections of 1000  µg 
cobalamin for 5  days. We advised a substitution of 
1000  µg cobalamin i.m. once a week for the following 
3 months, and afterward of 1000 µg/month i.m. Cobala-
min substitution was accompanied by an intake of folic 
acid (Fig. 3).
Outcome
Five months after the onset of therapy the patient com-
plained of a symmetric hypaesthesia of both upper 
extremities, reaching from both hands to the shoulders. 
Fig. 2 Magnetic resonance images of a patient suffering from subacute combined degeneration of spinal cord (SACD) before and after cobalamin 
substitution. a Before therapy: Sagittal and transversal T2-weighted images reveal an intraspinal hyper intensity of the dorsal cervical spinal cord 
(→) with no mass effect. No contrast enhancement of the lesion was found in T1-weighted images. b 5 months after the onset of cobalamin sub-
stitution: The hyper intensity completely disappeared. Known osteochondrosis and disc protrusion C5/6. In the sagittal view the transversal section 
plane is marked by a dotted line
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The hypaesthesia of the thorax had regressed. There 
were no other neurological problems and no behavioural 
abnormalities. At that time, serum level of cobalamin was 
710 pg/ml (Table 2).
MRI of the cervical spine revealed a complete regres-
sion of the intraspinal myelon lesion (Fig.  2b). Elec-
troneurography showed an axonal sensorimotor 
polyneuropathy of the upper and lower extremities.
After 11  months the patient reported paresthesia of 
both hands, the hypaesthesia of both arms had disap-
peared. Stereognosis of hands and feet was normal and 
two-point-discrimination was better (he recognized 
a distance of 4–5  cm at both arms and at the thorax). 
Bimalleolar vibration sense had improved from 0/8 to 
4–5/8 as assessed by the scale of the vibration tune (0 no 
sense, 8 full vibration sense).
Gastrin level was still elevated (730  pg/ml, normal: 
13–115 pg/ml), folic acid (10 ng/ml, normal: 3–20 ng/
ml), cobalamin (410  pg/ml, normal: 150–900  pg/ml), 
homocysteine (6.9  µmol/l, normal: 5.0–15.0  µmol/l) 
and MMA (178 nmol/l, normal: 50–300 nmol/l) were of 
normal range (Table  2). Blood picture was unremark-
able. MEP, SSEP and VEP revealed no abnormalities.
Conclusions
Initially, the report of an accident three months before 
the onset of symptoms combined with a cervical myelon 
lesion suggested a traumatic injury. A neoplastic cause 
was considered for differential diagnosis. However, the 
lesion of the cervical spine cord only affected the dorsal 
part of the myelon without any mass effect and did not 
show any uptake of contrast agent. Furthermore, a sub-
acute progress of disease was reported by the patient. 
Clinical examination revealed only sensory qualities 
conveyed by the posterior columns: hypaesthesia, reduc-
tion of two-point-discrimination, disturbed stereogno-
sis, and reduced vibration sensation. Therefore, SACD 
became probable. Now, diagnosis had to be confirmed by 
laboratory tests. The patient had a cobalamin level in the 
lower normal range. Several publications described the 
determination of serum cobalamin to be unreliable [2, 3, 
5, 18, 23, 24, 28, 29]. Therefore, other diagnostic markers 
are needed:
Adenosylcobalamin converts MMA to succinyl coen-
zyme A. Hence, cobalamin deficiency causes an excess of 
MMA [23]. Increased MMA values are highly sensitive 
and highly specific for cobalamin deficiency [28, 30].
For the degradation of homocysteine methylcobalamin, 
pyridoxine, and folic acid are needed. Therefore, hyper-
homocysteinemia gives a hint of a deficiency of all these 
vitamins, and has a high sensitivity but low specificity for 
cobalamin deficiency [28, 30]. The homocysteine level 
is suitable for follow-up and therapy monitoring [31]. It 
needs to be considered that blood has to be cooled for 
determining homocysteine levels.
Finally, a deficit of cobalamin causes a reduction of 
holoTC [2, 23, 32]. Lowered serum holoTC concentra-
tion is the earliest marker of cobalamin deficiency and is 
reduced even before any clinical symptoms are apparent 
[2, 32].
In our case increased values for MMA and homocyst-
eine were determined. After cobalamin substitution both 
values returned to normal. HoloTC was not measured, 
although we recommend its determination (Fig. 1).
The subsequent diagnostic provided prolonged laten-
cies for the left-hand medianus and double-sided tibialis 
SSEP. Read in conjunction with the diagnostic imaging 
this can be explained by lesions in the fasciculus gra-
cilis and cuneatus. MEP detected a central-motoric 
latency to the left arm pointing to an additional damage 
of the pyramidal tract. The elongated VEP give a hint 
for an undergoing demyelination of both optic nerves, 
which is sporadically associated with SACD. Neverthe-
less, our patient did not notice any visual limitations. 
In addition to the lesion in the cervical myelon, elec-
troneurography revealed the existence of an axonal 
Table 2 Laboratory values before and 11 month after cobalamin substitution
Despite distinct clinical findings of a subacute combined degeneration of spinal cord (SACD) and a profound intramedullar lesion shown by MRI, cobalamin was still 
in the normal range before therapy started. In contrast, homocysteine and methylmalonic acid are suitable parameters for SACD diagnostic. Methylmalonic acid is the 
most specific marker of a cobalamin deficiency. Homocysteine is suitable for follow-up and therapy monitoring. Just 5 month after therapy start clinical symptoms 
were declining and all pathological changes found by MRI in the spinal cord disappeared
Before cobalamin substitution 11 month after cobalamin substitution Normal range
Cobalamin (pg/ml) 197 410 150–900
Homocysteine (µmol/l) 50.8 6.9 5.0–15.0
Methylmalonic acid (nmol/l) 40,800 178 50–300
Folic acid (ng/ml) 18.7 10 3–20
Gastrin (pg/ml) 615 730 13–115
Parietal cell antibodies 1:640 – ≤1:20
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sensorimotor polyneuropathy, which is also common 
for a lack of cobalamin [33]. As expected in this context, 
liquor analysis did not reveal an infectious or chronic 
inflammatory process.
Gastroscopy and histology proved a type A gastritis 
with an increased value of gastrin. Serum gastrin is usu-
ally markedly increased as a result of gastric atrophy 
and the increase of pH value. Appropriately, parietal cell 
antibodies were found. Therefore, in this patient SACD 
was caused by a disruption of cobalamin processing in 
the stomach due to parietal cell antibodies inducing an 
increased pH-value and a decreased production of intrin-
sic-factor. Consequently, cobalamin could not dissolve 
out of the protein-bindings of the ingested food and was 
not bound to intrinsic factor.
Our patient presented solely sensory disturbances. No 
psychological disorders, no rhagades or gastrointestinal 
symptoms like Hunter glossitis, jaundice, diarrhea, dys-
pepsia or increased values of bilirubin were found. Moreo-
ver, no haematological alterations like macrocytosis were 
determined. A significant inverse correlation between the 
degree of anaemia and the severity of neurological involve-
ment that was independent of the duration of symptoms is 
known [5, 27]. The reasons for this finding are unclear.
Therefore, it is important to think of SACD when only 
sensory disturbances can be found, even if the value of 
cobalamin is normal.
Vitamin substitution removed the lesion and nearly all 
clinical symptoms of cervical spine cord within 5 months 
and provoked a restitution of hypaesthesia of the thorax 
within eleven months. Therapy recommendations con-
cerning dosage and mode of administration of cobalamin 
are inconsistent and depend on the underlying reason of 
vitamin deficiency [7, 24]. Figure  3 condenses our pre-
ferred treatment regime.
We reported on a patient with a large lesion in cer-
vical spine cord that matched with a subacute com-
bined degeneration of spinal cord (SACD). SACD 
was diagnosed by clinical signs and laboratory tests. 
When clinical signs suggest a lack of cobalamin, val-
ues of cobalamin might still be in the normal range. 
Therefore, it is important to determine more sensi-
tive parameters: HoloTC is the earliest and MMA the 
most specific marker of a cobalamin deficiency. Meas-
urement of homocysteine is inexpensive and there-
fore suitable for follow-up and therapy monitoring. 
Early and appropriate treatment reversed pathologi-
cal changes in the spinal cord and dissolved associated 
clinical symptoms.
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